It is important to have dermatology included throughout the undergraduate medical curriculum because most dermatologic problems are seen by nondermatologists. Respondents at each school believed that there may be value in moving toward a national strategy for dermatology curriculum changes, and this can ensure both uniformity and consistency within Canada.

Background: Acute generalized exanthematous pustulosis (AGEP) is a rare drug eruption presenting with an acute, extensive formation of nonfollicular sterile pustules on an erythematous and edematous base. Typically, the rash is accompanied by fever and leukocytosis, with spontaneous resolution in , 15 days. The incidence of AGEP is estimated at one to five cases per million people per year. Only 18% of these are from nonantibiotics. Hydroxychloroquine (HCQ) is an antimalarial agent that is also used to treat various dermatologic and rheumatologic conditions.Objective: We report the first observation in Canada of a patient with AGEP induced by HCQ.Methods and Results: AGEP was diagnosed in a 48-year-old female who had been taking HCQ for 2 weeks and then developed a diffuse erythematous and edematous pustular eruption. Clinical and pathologic findings were consistent with a diagnosis of AGEP.The patient was treated with steroids and supportive measures. The rash resolved after 18 days and a complicated course in hospital.Conclusion: AGEP is a rare drug eruption, usually to antibiotics. We report the first case in Canada of AGEP as an adverse reaction to HCQ. Clinicians should keep in mind the possibility of this severe skin eruption. Contexte: La pustulose exanthé mateuse aiguë gé né ralisé e (PEAG) est une é ruption rare, d'origine mé dicamenteuse, qui se manifeste par la formation é tendue et aiguë de pustules sté riles, non folliculaires, se dé veloppant sur un fond é rythé mateux et oedé mateux. Habituellement, l'é ruption cutané e, qui s'accompagne de fiè vre et de leucocytose, disparaît d'elle-mê me en moins de 15 jours. L'estimation de l'incidence de la PEAG est de 1 à 5 cas pour un million de personnes, par anné e; seuls 18% d'entre eux ne sont pas lié s à des antibiotiques. L'hydroxychloroquine (HCQ) est un antipaludique, mais elle sert aussi au traitement de diverses affections cutané es et rhumatismales. Objectif: Il s'agit ici de la premiè re observation d'une patiente atteinte de PEAG provoqué e par l'HCQ, au Canada. Mé thode et ré sultats: Un diagnostic de PEAG a é té posé chez une femme de 48 ans qui prenait de l'HCQ depuis 2 semaines et chez qui est apparue une é ruption diffuse de pustules é rythé mateuses et oedé mateuses. Les signes cliniques et pathologiques é taient compatibles avec ceux du diagnostic de PEAG. La patiente a é té traité e par les sté roïdes et des mesures d'appoint. L'é ruption est disparue au bout de 18 jours, aprè s un sé jour à l'hô pital pour des complications.Conclusions: La PEAG est une é ruption rare, d'origine mé dicamenteuse, gé né ralement attribuable aux antibiotiques. A é té exposé ici le premier cas de PEAG, au Canada, ré sultant d'une ré action dé favorable à l'HCQ. Les cliniciens devraient se rappeler cette possibilité devant des cas graves d'é ruption cutané e.

No abstract

There have been only two previous case reports presenting an association between AEGCG and temporal arteritis. This report explores AEGCG and its possible relationship to temporal arteritis along with possible treatment regimens cited in the current literature.

PCPs should receive more training to improve their ability in the diagnosis of malignant melanoma.

The number of dermatologists was a significant predictor of biomedical research production in the field of dermatology. This suggests that specialist availability may be one factor influencing dermatology research and publications.

Metastatic melanoma is an aggressive malignancy. Survival can be increased with the combination of BRAF and MEK inhibition. BRAF inhibitor-induced cutaneous toxicities can be attenuated with MEK inhibition. Here, we describe the first reported case of a patient with metastatic melanoma who developed granulomatous dermatitis and erythema induratum when treated with combination BRAF (vemurafenib) and MEK inhibitor (cobimetinib) therapy and discuss the clinical features and management of dermatologic side-effects secondary to BRAF +/– MEK inhibition.

NDGs should receive more dermatologic training in the recognition of malignant melanoma.